Exercise-Induced Pulmonary Hemorrhage (EIPH)

Exercise-Induced Pulmonary Hemorrhage (EIPH) is a common and significant respiratory disorder of performance horses, characterized by the presence of blood in the airways (trachea and bronchi) following strenuous exercise. The condition is most frequently observed in racing breeds, particularly Thoroughbreds, Standardbreds, and Quarter Horses, but can also affect horses in other disciplines such as eventing, show jumping, and polo. EIPH is a major cause of poor performance and is associated with substantial economic losses in the equine industry. The severity of EIPH ranges from subclinical (detected only by bronchoalveolar lavage or tracheal wash) to severe, with visible epistaxis (bleeding from the nostrils). The pathophysiology involves stress failure of pulmonary capillaries due to high pulmonary vascular pressures during intense exercise, leading to hemorrhage into the alveoli and airways. The condition is often recurrent, and while it is not typically fatal, it can significantly impair athletic performance and may lead to chronic pulmonary changes such as fibrosis and inflammation. EIPH is a multifactorial condition influenced by exercise intensity, pulmonary hemodynamics, and individual susceptibility. Management strategies include environmental modifications, pharmacological interventions (e.g., furosemide), and in some cases, surgical procedures such as the placement of a tracheal stent or the use of nasal strips. Despite extensive research, EIPH remains a challenging condition to prevent and treat effectively.

The primary etiology of EIPH is the mechanical stress failure of pulmonary capillaries resulting from extremely high pulmonary vascular pressures during maximal exercise. During intense exertion, cardiac output increases dramatically, leading to elevated pulmonary arterial and capillary pressures. The pulmonary capillaries, which are delicate structures, can rupture when the transmural pressure exceeds their structural integrity. This stress failure is exacerbated by the negative intrathoracic pressure generated during inspiration, which increases the pressure gradient across the capillary wall. Additional contributing factors include the high blood flow to the lungs during exercise, which can lead to regional overperfusion and increased shear stress. The condition is not caused by an infectious agent, but secondary inflammation can occur as a result of the hemorrhage. Other potential contributing factors include upper airway obstruction (e.g., laryngeal hemiplegia), which can increase negative pressure and worsen the condition, and environmental factors such as cold air or poor air quality. In some cases, underlying pulmonary diseases such as recurrent airway obstruction (heaves) or inflammatory airway disease (IAD) may predispose horses to EIPH by increasing capillary fragility. The exact molecular mechanisms involve disruption of the endothelial and epithelial basement membranes, leading to leakage of red blood cells into the alveolar spaces.

EIPH is extremely prevalent in racing horses, with studies reporting that up to 80-90% of Thoroughbred racehorses have evidence of EIPH on endoscopic examination after racing. The prevalence is similar in Standardbreds and Quarter Horses, though the severity may vary. The condition is more common in older horses, likely due to repeated exposure to high-intensity exercise and cumulative pulmonary damage. Both males and females are equally affected. EIPH is primarily a disease of performance horses, with a higher incidence in those that race at high speeds or over long distances. The condition is less common in horses used for lower-intensity disciplines, but it can still occur in eventers, show jumpers, and polo ponies. There is no strong breed predisposition beyond the racing breeds, but individual susceptibility varies. Environmental factors such as training on hard surfaces, poor ventilation in stables, and exposure to dust or allergens may increase the risk. The morbidity is high, but mortality is extremely low, with most horses surviving the condition. However, EIPH can lead to premature retirement from racing and significant economic losses. The recurrence rate is high, with many horses experiencing repeated episodes, especially if they continue to race at high intensity.

The pathophysiology of EIPH is centered on the stress failure of pulmonary capillaries. During maximal exercise, pulmonary arterial pressure can exceed 100 mmHg, and capillary pressure may reach 40-50 mmHg. The pulmonary capillaries are composed of a thin endothelial layer, a basement membrane, and an epithelial layer. When the transmural pressure exceeds the tensile strength of these structures, the capillaries rupture, allowing red blood cells to extravasate into the alveolar spaces. The rupture typically occurs in the dorsocaudal region of the lungs, which is the area with the highest blood flow and pressure. The hemorrhage can be mild, with only a few red blood cells in the alveoli, or severe, with frank blood filling the airways. The presence of blood in the alveoli triggers an inflammatory response, with recruitment of macrophages and neutrophils, leading to the release of pro-inflammatory cytokines and oxidative stress. Over time, repeated episodes of EIPH can lead to pulmonary fibrosis, hemosiderin deposition, and remodeling of the airways, which can impair gas exchange and lung compliance. The inflammation may also contribute to the development of bronchial hyperresponsiveness and airway obstruction. The exact biomechanical forces involved include the interaction between high capillary pressure and the negative intrathoracic pressure during inspiration, which increases the pressure gradient. Additionally, the uneven distribution of blood flow in the lungs may cause regional overperfusion, leading to localized stress failure. The condition is not associated with coagulopathies, as clotting parameters are normal in affected horses.

Several intrinsic and extrinsic factors predispose horses to EIPH. Intrinsic factors include age, with older horses being more susceptible due to cumulative pulmonary damage and decreased vascular elasticity. Breed and genetics play a role, as certain families of Thoroughbreds appear to have a higher incidence. High performance stress, such as racing at high speeds, is a major trigger. Extrinsic factors include environmental conditions such as cold air, which can cause bronchoconstriction and increase pulmonary vascular resistance, and poor air quality in stables, which can lead to chronic airway inflammation. Training practices, such as inadequate conditioning or sudden increases in exercise intensity, can also predispose to EIPH. Upper airway obstructions, such as laryngeal hemiplegia or dorsal displacement of the soft palate, increase the negative pressure in the thorax, exacerbating the stress on pulmonary capillaries. Additionally, concurrent respiratory diseases like inflammatory airway disease (IAD) or recurrent airway obstruction (RAO) can weaken the pulmonary capillary walls. Nutritional factors, such as vitamin C deficiency, may also play a role, although evidence is limited. Management factors, including the use of certain medications (e.g., non-steroidal anti-inflammatory drugs) that may affect platelet function, could theoretically increase the risk, but this is not well-established.

The clinical signs of EIPH vary depending on the severity of the hemorrhage. In mild cases, there may be no visible signs, and the condition is only detected by endoscopic examination of the trachea after exercise. In more severe cases, horses may exhibit epistaxis (bleeding from the nostrils) during or immediately after exercise. Other signs include poor performance, coughing, and increased respiratory effort. Some horses may show signs of respiratory distress, such as flared nostrils and increased respiratory rate. In severe cases, the horse may become anxious and reluctant to continue exercising. On physical examination, the horse may have an elevated heart rate and respiratory rate, and auscultation of the lungs may reveal crackles or wheezes, particularly in the dorsocaudal lung fields. The mucous membranes may be pale if significant blood loss has occurred, but this is rare. Endoscopic examination of the upper airways and trachea is the gold standard for diagnosis, and the severity is graded on a scale of 0 to 4 based on the amount of blood present. Grade 0 indicates no blood, Grade 1 is the presence of one or more flecks of blood, Grade 2 is a continuous stream of blood less than 10 cm in length, Grade 3 is a continuous stream of blood greater than 10 cm in length, and Grade 4 is the presence of blood pooling in the trachea or epistaxis. The clinical signs may be more pronounced in horses with concurrent respiratory disease.

The differential diagnoses for EIPH include other causes of epistaxis and respiratory bleeding. These include: 1) Guttural pouch mycosis, which is a fungal infection of the guttural pouch that can cause severe, often fatal, hemorrhage from the internal carotid artery. This condition is characterized by recurrent epistaxis, often at rest, and is diagnosed by endoscopic examination of the guttural pouches. 2) Ethmoid hematoma, a benign, progressive mass in the ethmoid region that can cause intermittent epistaxis. It is diagnosed by endoscopy and imaging. 3) Trauma to the head or upper respiratory tract, which can cause bleeding from the nasal passages or sinuses. 4) Coagulopathies, such as thrombocytopenia or von Willebrand disease, which can cause bleeding from multiple sites. 5) Pulmonary abscess or neoplasia, which can cause hemorrhage into the airways. 6) Severe exercise-induced pulmonary edema, which can cause respiratory distress and frothy blood-tinged fluid from the nostrils. 7) Upper airway obstruction, such as laryngeal hemiplegia, which can cause exercise intolerance and may be associated with EIPH. 8) Inflammatory airway disease (IAD) or recurrent airway obstruction (RAO), which can cause coughing and increased respiratory effort, but not typically frank bleeding. The key differentiating features include the timing of bleeding (during or after exercise vs. at rest), the presence of other clinical signs, and the results of endoscopic and imaging studies.

The diagnostic algorithm for EIPH begins with a thorough history and physical examination, with particular attention to the respiratory system. If EIPH is suspected, the horse should be exercised, and an endoscopic examination of the upper airways and trachea should be performed within 30 to 60 minutes after exercise to assess for the presence of blood. The severity is graded using the standard 0-4 scale. If the horse has epistaxis, a complete blood count and coagulation profile should be performed to rule out coagulopathies. Endoscopic examination of the guttural pouches is essential to rule out guttural pouch mycosis or ethmoid hematoma. If the diagnosis is unclear, a bronchoalveolar lavage (BAL) can be performed to detect the presence of red blood cells and hemosiderin-laden macrophages, which are indicative of previous hemorrhage. Thoracic radiography or ultrasonography may be useful to evaluate for other pulmonary abnormalities, such as pneumonia or masses. In some cases, a tracheal wash may be performed to assess for inflammation or infection. The diagnostic workup should also include a thorough evaluation of the upper airway to identify any obstructions that may contribute to EIPH. If the horse is a racehorse, a performance evaluation may be necessary to determine the impact of EIPH on racing ability. The diagnostic algorithm should be systematic and include all relevant tests to confirm the diagnosis and rule out other conditions.

Laboratory findings in EIPH are often non-specific but can support the diagnosis. A complete blood count (CBC) may reveal a mild anemia if there has been significant blood loss, but this is rare. Serum biochemistry may show elevated muscle enzymes (CK, AST) if the horse has exercised intensely, but these are not specific to EIPH. Arterial blood gas analysis may show hypoxemia (decreased PaO2) and hypercapnia (increased PaCO2) in severe cases, but these are not consistently present. Bronchoalveolar lavage (BAL) fluid analysis is the most useful laboratory test, as it can detect the presence of red blood cells and hemosiderin-laden macrophages. The presence of hemosiderin-laden macrophages indicates previous hemorrhage, and the percentage of these cells can be quantified. In horses with EIPH, the BAL fluid may also show an increased number of neutrophils, indicating inflammation. The total protein concentration in BAL fluid may be elevated. Tracheal wash cytology may also reveal red blood cells and hemosiderin-laden macrophages. Coagulation parameters, such as prothrombin time (PT) and activated partial thromboplastin time (aPTT), are typically normal in horses with EIPH, which helps rule out coagulopathies. Serum amyloid A (SAA) may be elevated if there is significant inflammation, but it is not specific. In summary, the laboratory findings are most useful when combined with endoscopic and cytological evidence of hemorrhage.

Imaging modalities are not routinely used for the diagnosis of EIPH, but they can be helpful in ruling out other conditions and assessing the severity of pulmonary changes. Thoracic radiography may show a diffuse interstitial pattern in the dorsocaudal lung fields, which is consistent with pulmonary hemorrhage and fibrosis. In severe cases, there may be evidence of pulmonary edema or consolidation. However, radiography is not sensitive enough to detect mild EIPH. Thoracic ultrasonography can be used to evaluate the pleural surface and may reveal comet-tail artifacts, which are indicative of alveolar hemorrhage. It can also be used to assess for the presence of pleural effusion or masses. Endoscopy is the primary imaging modality for diagnosing EIPH, as it allows direct visualization of the trachea and bronchi. The severity of hemorrhage is graded based on the amount of blood present. Bronchoscopy can also be used to collect BAL fluid. Computed tomography (CT) and magnetic resonance imaging (MRI) are not commonly used in equine practice due to the size of the horse and the need for general anesthesia, but they can provide detailed images of the lungs in research settings. Scintigraphy, using technetium-99m-labeled red blood cells, has been used in research to quantify the extent of pulmonary hemorrhage, but it is not widely available. In summary, imaging is most useful for ruling out other causes of respiratory bleeding and for monitoring the chronic changes associated with EIPH.

Cytological and histopathological findings are important for confirming the diagnosis of EIPH and assessing the chronicity of the condition. Bronchoalveolar lavage (BAL) fluid cytology is the most commonly used diagnostic test. In horses with EIPH, the BAL fluid will contain red blood cells, and the presence of hemosiderin-laden macrophages is a hallmark finding. Hemosiderin is a breakdown product of hemoglobin, and its presence indicates that hemorrhage has occurred in the past. The percentage of hemosiderin-laden macrophages can be quantified, and a value greater than 10% is considered significant. The BAL fluid may also show an increased number of neutrophils, which indicates inflammation. In chronic cases, there may be evidence of fibrosis, with an increased number of fibroblasts and collagen. Tracheal wash cytology may also reveal red blood cells and hemosiderin-laden macrophages, but it is less sensitive than BAL. Histopathological examination of lung tissue, obtained at necropsy or via biopsy, shows the characteristic lesions of EIPH, including alveolar hemorrhage, hemosiderin deposition, and fibrosis. The lesions are typically most severe in the dorsocaudal lung fields. There may be evidence of bronchial and bronchiolar inflammation, with infiltration of lymphocytes and plasma cells. In severe cases, there may be pulmonary arterial remodeling, with thickening of the vessel walls. These histopathological changes are consistent with the chronic, recurrent nature of EIPH.

The treatment of EIPH is primarily aimed at reducing the severity of hemorrhage and managing the underlying inflammation. The most widely used pharmacological agent is furosemide (Lasix), a loop diuretic that is administered intravenously approximately 4 hours before exercise. Furosemide reduces pulmonary vascular pressure by decreasing blood volume and increasing urine output, thereby reducing the stress on pulmonary capillaries. The recommended dose is 0.5 to 1.0 mg/kg IV, and it is often used in conjunction with other medications. Furosemide is permitted in many racing jurisdictions, but its use is regulated. Other treatments include the use of nasal strips, which are applied to the nares to reduce upper airway obstruction and decrease the negative pressure in the thorax. Environmental management, such as improving ventilation in stables and reducing dust exposure, can help reduce airway inflammation. In cases of severe EIPH, rest may be necessary to allow the lungs to heal. Anti-inflammatory medications, such as non-steroidal anti-inflammatory drugs (NSAIDs) like flunixin meglumine (1.1 mg/kg IV) or phenylbutazone (2.2 mg/kg PO), may be used to reduce inflammation, but they do not directly prevent hemorrhage. Corticosteroids, such as dexamethasone (0.04-0.1 mg/kg IV), may be used in severe cases to reduce inflammation, but their use is controversial due to potential side effects. In some cases, surgical intervention may be considered, such as the placement of a tracheal stent or the use of a laryngeal tie-forward procedure to address upper airway obstruction. However, these procedures are not commonly performed for EIPH. The primary goal of treatment is to minimize the impact of EIPH on performance and to prevent the development of chronic pulmonary changes.

The prognosis for horses with EIPH is generally good, as the condition is not typically life-threatening. However, the prognosis for continued athletic performance is guarded, as EIPH can lead to poor performance and premature retirement. The severity of the hemorrhage, as assessed by endoscopic grading, is a significant prognostic indicator. Horses with mild EIPH (Grade 1-2) may continue to race successfully, while those with severe EIPH (Grade 3-4) are more likely to have reduced performance. The recurrence rate is high, and many horses will experience repeated episodes, especially if they continue to race at high intensity. The development of chronic pulmonary changes, such as fibrosis, can further impair respiratory function and reduce performance. The response to treatment, particularly the use of furosemide, can also influence the prognosis. Horses that respond well to furosemide may have a better prognosis for continued racing. The overall survival rate is excellent, and most horses do not die from EIPH. However, the economic impact of EIPH is significant, as affected horses may lose value and incur costs for treatment and management. Negative prognostic indicators include the presence of epistaxis, which is associated with more severe hemorrhage, and the development of chronic respiratory disease. In summary, the prognosis for life is excellent, but the prognosis for athletic performance is variable and depends on the severity and frequency of episodes.

Follow-up care for horses with EIPH is essential to monitor the condition and adjust management strategies. After an episode of EIPH, the horse should be rested for a period of time, typically 1-2 weeks, to allow the lungs to heal. The horse should be gradually returned to exercise, with a structured rehabilitation program that includes increasing exercise intensity over several weeks. Regular endoscopic examinations should be performed after exercise to assess the severity of EIPH and monitor for recurrence. If the horse is racing, endoscopic examinations should be performed after each race to document the presence and severity of EIPH. The use of furosemide should be evaluated on an individual basis, and the timing and dose should be adjusted as needed. Environmental management, such as improving ventilation and reducing dust, should be maintained to minimize airway inflammation. The horse should be monitored for signs of respiratory disease, such as coughing or nasal discharge, and any underlying conditions, such as IAD or RAO, should be treated appropriately. Regular veterinary check-ups, including thoracic auscultation and possibly BAL, may be recommended to assess the progression of the condition. The farriery schedule should be maintained, as hoof health can affect overall performance. The horse's diet should be balanced, with adequate vitamins and minerals to support respiratory health. In summary, follow-up care is focused on monitoring the condition, preventing recurrence, and maintaining the horse's overall health and performance.

Clinical pearls for managing EIPH include: 1) Always perform endoscopic examination within 30-60 minutes after exercise to accurately grade EIPH, as blood may be cleared from the airways over time. 2) Use furosemide at the appropriate dose and timing (4 hours before exercise) to maximize its efficacy. 3) Consider the use of nasal strips to reduce upper airway obstruction and decrease the negative pressure in the thorax. 4) Address any concurrent upper airway obstructions, such as laryngeal hemiplegia, as they can exacerbate EIPH. 5) Monitor for chronic pulmonary changes, such as fibrosis, which can impair performance. 6) Educate owners and trainers about the high prevalence of EIPH and the importance of early detection. Pitfalls to avoid include: 1) Failing to perform endoscopic examination after exercise, which can lead to underdiagnosis. 2) Using furosemide at the wrong time or dose, which can reduce its effectiveness. 3) Ignoring environmental factors, such as poor air quality, which can worsen the condition. 4) Overlooking other causes of epistaxis, such as guttural pouch mycosis, which can be life-threatening. 5) Returning the horse to exercise too quickly after an episode, which can lead to recurrence. 6) Relying solely on clinical signs, as many horses with EIPH show no visible signs. 7) Failing to consider the impact of EIPH on performance, which can lead to frustration and mismanagement.

The primary drug used for the prevention and management of EIPH is furosemide (Lasix). The recommended dose is 0.5 to 1.0 mg/kg administered intravenously (IV) approximately 4 hours before exercise. Furosemide is a loop diuretic that reduces pulmonary vascular pressure by decreasing blood volume. It is important to note that furosemide is a controlled substance in many racing jurisdictions and must be used in accordance with regulations. Other medications that may be used include: 1) Non-steroidal anti-inflammatory drugs (NSAIDs) such as flunixin meglumine (1.1 mg/kg IV) or phenylbutazone (2.2 mg/kg PO) to reduce inflammation, but they do not prevent hemorrhage. 2) Corticosteroids such as dexamethasone (0.04-0.1 mg/kg IV) may be used in severe cases to reduce inflammation, but their use is controversial due to potential side effects. 3) Bronchodilators such as clenbuterol (0.8-3.2 mcg/kg PO) may be used to improve airway function, but they are not specifically indicated for EIPH. 4) Antioxidants such as vitamin C (10-20 g/day PO) may be used to reduce oxidative stress, but evidence is limited. 5) In some cases, the use of aminocaproic acid (a fibrinolytic inhibitor) has been suggested, but its efficacy is not well-established. The use of nasal strips is a non-pharmacological intervention that can be applied to the nares to reduce upper airway obstruction. It is important to note that the use of any medication in performance horses must comply with the rules of the relevant racing authority. The dosages and intervals should be adjusted based on the individual horse's response and the severity of EIPH.

The literature on EIPH is extensive, with numerous studies investigating the pathophysiology, diagnosis, and treatment of the condition. Key landmark studies include: 1) The study by Pascoe et al. (1981) which first described the endoscopic grading system for EIPH. 2) The work of West et al. (1993) which elucidated the biomechanical stress failure of pulmonary capillaries as the primary mechanism of EIPH. 3) The study by Hinchcliff et al. (2005) which demonstrated the efficacy of furosemide in reducing the severity of EIPH in racing Thoroughbreds. 4) The consensus statement by the American College of Veterinary Internal Medicine (ACVIM) on EIPH, which provides guidelines for diagnosis and management. 5) The study by Sweeney et al. (1990) which evaluated the use of bronchoalveolar lavage in diagnosing EIPH. 6) The research by Poole et al. (2000) which investigated the effects of exercise on pulmonary hemodynamics. 7) The study by Couëtil et al. (2016) which reviewed the evidence for various treatments, including furosemide and nasal strips. 8) The meta-analysis by Sullivan et al. (2015) which assessed the prevalence of EIPH in racing horses. These studies have contributed to our understanding of EIPH and have informed clinical practice. The consensus is that furosemide is the most effective treatment for reducing the severity of EIPH, but it does not completely prevent it. Environmental management and addressing concurrent respiratory conditions are also important. Further research is needed to develop more effective preventive strategies and to understand the long-term consequences of EIPH.